Alerta

USE OF A MEDICAMENT SIMULTANEOUSLY TARGETING THE TYROSINE KINASE ACTIVITY AND GEF ACTIVITY OF EGFR

Resumen de: EP4817602A1

The present invention provides an EGFR inhibitor for use in the preparation of a medicament for treating diseases mediated by guanosine exchange factor (GEF) activity or co-mediated by guanosine nucleotide exchange factor (GEF) activity and EGFR tyrosine kinase activity, wherein the diseases are selected from the group consisting of: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia, and glioblastoma. Specifically, the present invention has discovered that in addition to its conventional tyrosine kinase activity, EGFR also possesses a GEF function that promotes the activation of Ras homologous protein (Rheb), this function is independent of its tyrosine kinase activity and relies critically on the glutamate residue at position 804 on the EGFR molecule. The Rheb-GEF activity of EGFR induces allosteric activation of mammalian target of rapamycin complex 1 (mTORC1), ultimately promoting tumor growth.

BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

Resumen de: NL4002684A

0001 ABSTRACT Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an 5 epitope of BCMA are administered to the subject.

HYDROXYLAMINE-BASED BCR-ABL1 INHIBITORS FOR TREATMENT OF CANCER

Resumen de: US20260297031A1

0000 In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit breakpoint cluster region, chromosome 22 (BCR) and Abelson proto-oncogene 1, chromosome 9 (ABL1) in a subject, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers involving aberrant BCR and ABL1 activity. In another aspect, the compounds described herein can evade P-gp-mediated efflux in a subject, which makes the compounds effective in treating a Philadelphia chromosome positive (Ph+) leukemia.

MULTIPLE MYELOMA TREATMENT

Resumen de: US20260294848A1

0000 The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

COMPOSITIONS OF MRNA-ENCODED VIRUS-LIKE PARTICLES, COMPOSITIONS OF MRNA-LIPID NANOPARTICLES, AND METHODS FOR USE THEREOF

Resumen de: US20260295033A1

An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.

COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER

Resumen de: US20260294951A1

0000 The present disclosure provides compositions (e.g., injectable compositions) comprising fludarabine (e.g., fludarabine phosphate), and methods of using same to treat cancers, such as a lymphoma, and/or to lymphodeplete a subject in need thereof, for example in association with a CAR-T therapeutic regimen.

Keratin YK93-5, Preparation Method, and Pharmaceutical Composition and Use Thereof

Resumen de: US20260297148A1

The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a genome integrated with the nucleic acid molecule, a preparation method for the keratin YK93-5, and a pharmaceutical composition of the keratin YK93-5, and further provides a use of the products such as the keratin YK93-5 in the preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroids, prostatic hyperplasia, etc.

Keratin YK93-2, and Preparation Method Therefor, Pharmaceutical Composition Thereof and Use Thereof

Resumen de: US20260297147A1

The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector including the nucleic acid molecule, a host cell including the expression vector or the genome integrated with the nucleic acid molecule, a preparation method therefor and a pharmaceutical composition thereof. Further provided is the use of the above-mentioned product, such as keratin YK93-2 in the preparation of a drug for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroid, prostatic hyperplasia etc.

1,3,4-THIADIAZOL-2-YL CARBOXAMIDE AND 1,3-THIAZOL-2-YL CARBOXAMIDE COMPOUNDS AND USES THEREOF AS INHIBITORS OF HUMAN POLYMERASE THETA

Resumen de: US20260294921A1

0000 The present application discloses specific compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and their use in therapy, in particular, their use as human polymerase theta (Polθ) inhibitors for the treatment of hyperproliferative diseases including cancers such as carcinoma, sarcoma, adenocarcinoma, leukemia, lymphoma, and melanoma, and pre-malignant conditions. The application further discloses the use of a compound of formula (I), in combination with an additional anticancer therapy. 0000

IMMUNOTHERAPEUTICS BASED ON MAGEA1-DERIVED EPITOPES

Resumen de: US20260297156A1

0000 The present invention relates to the field of immunotherapy, in particular, adoptive T cell therapy of MAGEA1-associated cancer. TCR alpha chain constructs (TRA) and/or a TCR beta chain constructs (TRB) of TCR constructs specific for an epitope in complex with a human MHC-I, wherein the epitope is an epitope of a MAGEA1 protein, nucleic acids encoding them and host cells expressing them. The invention also provides pharmaceutical compositions or kits based theron. The invention teaches combinations of TCR constructs directed to different epitopes from the same antigen expressed by the same cancer or infectious agent capabel of being presented by different MHC-I molecules, wherein optionally, the antigen is MAGEA1. Preferably, at least one of the TCR constructs used in the combination is a TCR construct of the invention disclosed herein. The pharmaceutical combinations or kits may be used for immunotherapy of a subject, e.g., adoptive T cell therapy or TCR gene therapy, e.g., for use in treatment of a cancer such as lung cancer, colorectal cancer, or multiple myeloma. The invention also provides peptides comprising the epitopes recognized by the TCR constructs of the invention, which may be for use in vaccination, e.g., peptide vaccination or RNA vaccination.

MENIN-MLL INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2026200437A1

Disclosed in the present invention are a Menin-MLL inhibitor, a preparation method therefor and the use thereof. The inhibitor can be used for the treatment of related diseases (in particular, hematological tumors (such as leukemia) and diabetes), and has excellent application prospects and research value.

ANTI-B-CELL MATURATION ANTIGEN (BCMA) BINDING DOMAINS AND USES THEREOF

Resumen de: WO2026207156A1

Anti-B-cell maturation antigen (BCMA) binding domains and uses thereof are provided. The binding domains can be used to target such cells expressing BCMA ex vivo or in vivo for research, diagnostic, or therapeutic purposes, for example in the treatment of multiple myeloma.

KAT6A, KAT6B, AND KAT7 INHIBITORS AND USES THEREOF

Resumen de: WO2026202706A1

The present invention provides compounds of Formula I:, I which are useful for the inhibition of KAT6A, KAT6B, and/or KAT7. Compounds of Formula I are useful for the treatment of cancer, including bladder cancer, breast cancer, cervical cancer, colorectal cancer including colon and rectal adenocarcinomas, leukemias including acute myeloid leukemia (AML), lung adenocarcinoma, medulloblastoma, osteosarcoma, ovarian cancer, and prostate cancer.

CARS AND CAR-NK CELLS TARGETING BOTH BCMA AND GPRC5D AND USE THEREOF IN TREATING MULTIPLE MYELOMA

Resumen de: WO2025108429A1

A chimeric antigen receptors (CARs) and CAR-NK cells targeting both BCMA and GPRC5D and use thereof in treating multiple myeloma (MM) is provided. In particular, the disclosure relates to bi-specific CARs comprising: (a) a B-cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor of family C, group 5, member D (GPRC5D) targeting domain, preferably armored with such as IL15, and the corresponding coding polynucleotides for the CARs and vectors comprising the polynucleotides. Also provided is CAR-NK cell modified with the CAR (s), and use of the CAR and CAR-NK cell in the treatment of MM.

BISPECIFIC CD33 AND CD3 BINDING PROTEINS

Resumen de: EP4813396A2

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33⁺ cancers, diseases and conditions such as acute myeloid leukemia (AML).

EDELFOSINE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA

Resumen de: EP4813380A1

The present invention relates to the use of the alkyl phospholipid edelfosine (especially (S)-edelfosine) in the treatment of multiple myeloma.

ANTI-BCMA SINGLE DOMAIN ANTIBODIES, NANO-CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF

Resumen de: WO2026198533A1

The present disclosure concerns methods and compositions related to sdAbs targeting BCMA. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of BCMA is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of multiple myeloma (MM) and/or B-cell lymphoproliferative disorders and other cancers that express BCMA.

TREATMENT OF RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WITH A COMBINATION COMPRISING GLOFITAMAB, GEMCITABINE AND OXALIPLATIN

Resumen de: AU2025255746A1

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

COMPOSITIONS FOR TREATMENT OF CANCER AND USES THEREOF

Resumen de: AU2026220660A1

The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.

ANTLCYCLIN SINGLE DOMAIN ANTIBODIES, NANO-CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF

Resumen de: WO2026198571A1

The present disclosure concerns methods and compositions related to sdAbs targeting cyclin. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of cyclin is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or T/NK-cell engager therapy or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of acute myeloid leukemia and other cancers that express cyclin.

RECRUITMENT AND ACTIVATION OF CAR-REDIRECTED INVARIANT NATURAL KILLER T CELLS

Resumen de: WO2026198634A1

The invention provides an invariant natural killer T (iNKT) cell-targeted microparticle recruitment and activation system (iMRAS), one which provides a biomimetic platform that enhances iNKT cell functionality through localized immunostimulation in vivo. This biomimetic platform is designed to function as an in vivo "charging station" containing chemotactic and activation signals for the recruitment, activation, and expansion of CAR-iNKT cells, leading to more effective tumor killing and longer persistence of CAR-iNKT cells, as demonstrated in lymphoma and melanoma. Through its biomimetic design and localized immunostimulatory effects, iMRAS helps overcome the limitations of current therapies for solid tumors, establishing a robust platform for enhancing systemic CAR-iNKT cell-mediated immunotherapy.

MODIFIED CST6 POLYPEPTIDES AND CELLS INCLUDING THESE POLYPEPTIDES FOR CANCER TREATMENT

Resumen de: WO2026198989A1

Provided herein are modified cystatin M/E (CST6) polypeptides or fragments thereof comprising a mutation as well as polynucleotide constructs encoding the same or cells comprising the same. Chimeric Antigen Receptor (CAR) T cells expressing the modified CST6 polypeptide are also provided. The disclosure further encompasses methods for use in treatment of cancer including multiple myeloma and methods of inhibiting or reducing bone loss using the compositions provided herein. Methods of maintaining CAR T cells receptor expression and methods of inducing immune responses using the compositions are also provided.

CIK CELLS EXPRESSING CAR AND A CXCL8 CHEMOKINE RECEPTOR AND THERAPEUTIC USES THEREOF

Resumen de: WO2026195557A1

A therapeutic composition is described containing CIK (Cytokine-Induced Killer) cells engineered to express a Chimeric Antigen Receptor (CAR) against an antigen present on acute myeloid leukaemia cancer cells and at least one interleukin-8 (IL-8) receptor. Other aspects of the invention relate to the engineered CIK cells and the use thereof in the treatment of acute myeloid leukaemia.

SMALL PEPTIDE, FAST-OFF CHIMERIC ANTIGEN RECEPTOR TO ROR1 FOR CANCER

Resumen de: WO2026198924A1

The present invention describes ROR1 peptide binders and chimeric antigen receptor (CAR) cells expressing these binders. Also described are methods of producing T-lymphocyte (T-cell) expressing the CARs, and method of producing a natural killer (NK) cell expressing the CARs. Further described are methods of eliminating ROR1 positive cells and methods of eliminating myeloma cells, pancreatic cancer cells, or lymphoma cells. Methods of treating ROR1 positive cancers are also described herein.

ANTI- GPRC5D, ANTI-FCRH5 SDABS, AND NANO-CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF

Nº publicación: WO2026198551A1 24/09/2026

Solicitante:

BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

Resumen de: WO2026198551A1

The present disclosure concerns methods and compositions related to sdAbs targeting GPRC5D and FCRH5. The sdAbs may be utilized in immunotherapies of any kind and for any medical application in which targeting of GPRC5D or FCRH5 is therapeutic. The sdAbs may be utilized as naked monoclonal antibodies or modified further or use as antibody-drug conjugate or T/NK-cell engager therapy or as chimeric antigen receptor (CAR) cell therapy. Embodiments include therapy of multiple myeloma (MM) and/or B-cell lymphoproliferative disorders and other cancers that express GPRC5D or FCRH5.